Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the…
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained…
For years, healthcare organizations have focused on enabling clinical mobility by giving clinicians access to systems, communication tools, and patient…
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in…
In the first part of our Q&A with Grace Breen, SVP, Quality, Sharp, we explored valuable insights derived from her…
CGTs offer potentially life-changing treatment for a broad spectrum of complex diseases, from genetic conditions to cancers. The pace of…